13:53 , Apr 1, 2019 |  BC Extra  |  Clinical News

Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic pancreatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a new...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
23:45 , Apr 20, 2018 |  BioCentury  |  Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
22:59 , Apr 6, 2018 |  BC Extra  |  Preclinical News

Tumor immune microenvironment could predict prognosis

A team led by researchers from the Cancer Research Institute, Institute for Systems Biology and Sage Bionetworks have identified six immune subtypes of tumors that they said could encompass nearly all human malignancies and delineate...
23:08 , Mar 12, 2018 |  BC Extra  |  Preclinical News

Getting more out of GWAS hits

A new study led by The Institute of Cancer Research presents a high throughput method for mapping hits from genome-wide association studies (GWAS) to the genes they modulate. GWAS can link genetic loci to disease...
17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor...
23:24 , Jan 26, 2018 |  BioCentury  |  Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
20:44 , Dec 7, 2017 |  BC Extra  |  Clinical News

Cancer Research Institute publishes analysis of immuno-oncology field

Cancer Research Institute performed a deep dive of immuno-oncology development and found that while there are a number of promising therapies, the field is inefficient and filled with duplicate and uncoordinated trials. In a report...
21:30 , Sep 29, 2017 |  BC Week In Review  |  Company News

Cancer Research, Parker Institute partner to test I-O combos for pancreatic cancer

CRI and the Parker Institute for Cancer Immunotherapy partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Apexigen Inc. (San Carlos, Calif.) to evaluate combinations of immunotherapies with chemotherapy to treat pancreatic cancer. The partners started a...